No products in the cart.
Pre-made Foralumab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-220
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon. Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn’s disease and other autoimmune diseases.
| Products Name (INN Index) | Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Foralumab |
| Target | CD3E |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Medarex,NovImmune SA,Harvard Medical School,Tiziana Life Sciences |
| Conditions Approved | NA |
| Conditions Active | Crohn's disease,Neurodegenerative disorders,Primary biliary cirrhosis,Inflammatory bowel diseases,Non-alcoholic steatohepatitis,Type 2 diabetes mellitus |
| Conditions Discontinued | Transplant rejection,Type 1 diabetes mellitus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD3E |
| Package |
Previous slide
Next slide
